Future Considerations for the Management of Hyperlipidemia

Anticipated Impacts of Updated Cholesterol Guidelines on Clinical Practice

Key Considerations for Physicians

The upcoming cholesterol guideline updates are likely to significantly impact clinical practice in several ways:

• Evolving LDL-C target levels: Expect potential lowering of target LDL-C levels, especially for highest-risk patients, possibly below the current 70 mg/dL or 55 mg/dL thresholds
• Risk stratification refinement: New guidelines may introduce more nuanced risk assessment tools that better identify patients who would benefit most from intensive lipid-lowering therapy
• Integration with cardiovascular-kidney-metabolic health (CKM) framework: The CKM paradigm will likely influence cholesterol management by:
  • Promoting more comprehensive patient evaluation beyond traditional atherosclerotic cardiovascular disease risk factors
  • Recognizing kidney disease and metabolic disorders as critical risk enhancers
  • Suggesting differential treatment approaches for patients with diabetes, chronic kidney disease, or metabolic syndrome
• Expanded role of nonstatin therapies: Updated guidelines may provide clearer recommendations for sequencing therapies, including earlier consideration of PCSK9 inhibitors and ezetimibe for high-risk patients
• Greater emphasis on residual risk: More attention to addressing residual cardiovascular risk despite achieving LDL-C target levels, potentially incorporating inflammation markers and other lipid parameters

Conclusion

These anticipated changes will require physicians to adopt more personalized approaches to cholesterol management that consider the interconnected nature of cardiovascular, kidney, and metabolic health.